What was the overall valuation of the US antiemetics market in 2024?

The overall market valuation was $8.0 Billion in 2024. Read More

What is the projected market valuation for the US antiemetics market by 2035?

The projected valuation for 2035 is $12.6 Billion. Read More

What is the expected CAGR for the US antiemetics market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 4.22%. Read More

Which drug class segment had the highest valuation in 2024?

The Serotonin 5-HT3 Receptor Antagonists segment had the highest valuation at $2.4 Billion in 2024. Read More

What is the projected valuation for the Oral route of administration by 2035?

The projected valuation for the Oral route of administration is $3.8 Billion by 2035. Read More

Which end user segment is expected to grow the most by 2035?

The Pharmacies segment is expected to grow the most, with a projected valuation of $4.3 Billion by 2035. Read More

What was the valuation of the Cannabinoids segment in 2024?

The Cannabinoids segment was valued at $1.0 Billion in 2024. Read More

How much is the Postoperative Nausea and Vomiting indication projected to be worth by 2035?

The Postoperative Nausea and Vomiting indication is projected to be worth $2.5 Billion by 2035. Read More

Which company is one of the key players in the US antiemetics market?

Roche is one of the key players in the US antiemetics market. Read More

What was the valuation of the Neurokinin-1 Receptor Antagonists segment in 2024?

The Neurokinin-1 Receptor Antagonists segment was valued at $1.8 Billion in 2024. Read More

US Antiemetics Market

ID: MRFR/HC/18034-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Antiemetics Market Research Report: Size, Share, Trend Analysis By Drug Class (Serotonin 5-HT3 Receptor Antagonists, Dopamine Antagonists, Antihistamines, Cannabinoids, Neurokinin-1 Receptor Antagonists), By Route of Administration (Oral, Intravenous, Transdermal, Rectal, Subcutaneous), By Indication (Chemotherapy-Induced Nausea, Postoperative Nausea and Vomiting, Motion Sickness, Pregnancy-Related Nausea, Radiation-Induced Nausea) and By End Users (Hospitals, Clinics, Homecare Settings, Pharmacies) - Growth Outlook & Industry Forecast 2025 To 2035

US Antiemetics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.22%

2024 Market Size$ 8 Billion

2025 Market Size$ 8.34 Billion

2035 Market Size$ 12.6 Billion

Key Players

Roche

Novartis

GlaxoSmithKline

Bristol-Myers Squibb

Merck & Co.

AstraZeneca

Trends

Rising Demand for Personalized Medicine
Technological Advancements in Drug Delivery
Increased Focus on Chronic Illness Management

Opportunities

Advancements in Drug Formulations
Increasing Healthcare Expenditure
Rising Awareness of Nausea Management

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Drug Class (USD Billion)
  1. 4.1.1 Serotonin 5-HT3 Receptor Antagonists
  2. 4.1.2 Dopamine Antagonists
  3. 4.1.3 Antihistamines
  4. 4.1.4 Cannabinoids
  5. 4.1.5 Neurokinin-1 Receptor Antagonists
2. 4.2 Healthcare, BY Route of Administration (USD Billion)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Transdermal
  4. 4.2.4 Rectal
  5. 4.2.5 Subcutaneous
3. 4.3 Healthcare, BY Indication (USD Billion)
  1. 4.3.1 Chemotherapy-Induced Nausea
  2. 4.3.2 Postoperative Nausea and Vomiting
  3. 4.3.3 Motion Sickness
  4. 4.3.4 Pregnancy-Related Nausea
  5. 4.3.5 Radiation-Induced Nausea
4. 4.4 Healthcare, BY End User (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Homecare Settings
  4. 4.4.4 Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US US Antiemetics Market Segmentation

US Antiemetics Market By Drug Class (USD Billion, 2025-2035)

Serotonin 5-HT3 Receptor Antagonists
Dopamine Antagonists
Antihistamines
Cannabinoids
Neurokinin-1 Receptor Antagonists

US Antiemetics Market By Route of Administration (USD Billion, 2025-2035)

Oral
Intravenous
Transdermal
Rectal
Subcutaneous

US Antiemetics Market By Indication (USD Billion, 2025-2035)

Chemotherapy-Induced Nausea
Postoperative Nausea and Vomiting
Motion Sickness
Pregnancy-Related Nausea
Radiation-Induced Nausea

US Antiemetics Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Homecare Settings
Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”